Protalex, Inc. Completes Analysis of Data from Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthritis

SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical stage biopharmaceutical company focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including rheumatoid arthritis (RA), today announced results from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study. The study conducted in South Africa of PRTX-100 in adult patients with active RA demonstrated that the drug was generally safe and well-tolerated at all dose levels and at the higher doses, more patients showed improvement in their CDAI (Clinical Disease Activity Index for RA) than did patients at the lower dose or placebo cohorts.